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Summary. Background:Underhighshearstressplateletsadhere
preferentiallytotheadventitialayerofthearterialvesselwallina
von Willebrand factor (VWF)-dependent manner. Objective:
The present study was undertaken in an attempt to characterize
the structural background of the relative thromboresistance of
the media and the impact of neutrophil leukocyte-derived
proteases (matrix metalloproteinases, neutrophil elastase) on
plateletadhesioninthislayerofthearteries.Methodsandresults:
Platelet adhesion to cross-sections of the human iliac artery was
monitored by indirect immunoﬂuorescent detection of GpIIb/
IIIaantigen.Exposureofthevesselwalltoactivatedneutrophils
orneutrophil-derivedproteasesincreasedplateletadhesiontothe
media about tenfold over the control level at 3350 s
)1 surface
shear rate. In parallel with this enhanced thrombogenicity
morphological changes in the media were evidenced by atomic
force microscopy (AFM) and scanning electron microscopy
(SEM). The ﬁne proteoglycan meshwork seen with Cuprome-
ronicBlueenhancementoftheSEMimageswasremovedbythe
proteolytictreatmentandthetypicalcollagenﬁberstructurewas
exposedontheAFMimagesofthemedia.Conclusion:Through
their proteases activated neutrophils degrade proteoglycans,
unmask VWF binding sites and thus abolish the thromboresis-
tance of the media in human arteries.
Keywords: collagen, neutrophil granulocytes, platelets, prote-
ases, proteoglycans, vascular media.
Introduction
Platelets are essential for normal hemostasis and their function
is particularly relevant to arrest bleeding in the small arterioles
of 10–50 lM in diameter, where the wall shear rate varies from
500 to 5000 s
)1, representing the highest values in normal
circulation [1]. Under these conditions the initial platelet
recruitment is von Willebrand factor (VWF)-dependent;
platelet adhesion is initiated by the binding of platelet GpIb
to VWF immobilized on the thrombogenic surface [2–4]. This
interaction slows down platelets sufﬁciently enough to enable
GpVI-collagen-mediated platelet signaling which leads to the
activation of GpIIb/IIIa, a receptor required for platelet
aggregation [5]. VWF circulates in plasma in a multimeric form
containing a variable number of subunits, distinct domains of
which bind platelet surface glycoproteins GpIb and GpIIb/
IIIa, as well as collagen types I, III and VI [6–8]. The vessel wall
is enriched in type I and III ﬁbrillar collagens, which are highly
thrombogenic matrices, but this property may be inﬂuenced by
other extracellular matrix components, for instance by prote-
oglycans. The proteoglycan distribution is different in distinct
vessel layers, including mainly versican and decorin in the
adventitia and versican, biglycan and perlecan in the media [9–
15]. The media layer of human arterial vessel wall is resistant to
platelet adhesion under high shear rate and the platelets adhere
mainly to the adventitia [16]. However, after treatment with
serine-proteases (trypsin, chymotrypsin and proteinase 3) or
with chondroitinase ABC a seven- to tenfold increase in the
VWF-mediated platelet adhesion to the collagen of the media is
observed [16,17].
Adherent platelets recruit leukocytes from circulating blood,
predominantly neutrophils, representing 76% of the leukocytes
in thrombi [18] followed by activation of the thrombus-bound
cells [19]. The initial interaction is P-selectin-dependent which
binds to its leukocyte ligand PSGL-1 [20]. The interaction is
strengthened by activation of an integrin receptor (aMß2)v i a
tyrosine phosphorylationmediated by srckinases that increases
aMß2-mediated binding to platelets [21]. Platelets also release
microparticles with platelet-speciﬁc receptors and P-selectin,
which promote platelet–platelet and platelet–leukocyte aggre-
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  2010 International Society on Thrombosis and Haemostasisgation [22–24]. Thrombogenesis is supported by the platelet
activating effects of cathepsin G released in the course of
degranulation of the activated neutrophils together with
neutrophil elastase [25,26]. Upon activation, neutrophils may
release their secondary granule content including members of
the metalloproteinase (MMP) family (interstitial collagenase,
MMP-8 and gelatinase B, MMP-9) [27–30], but little is known
about the potential impact of these proteases on the growing
thrombus. The present study attempts to characterize the
effects of neutrophils on the initial, VWF-dependent platelet
adhesion to the vessel wall at a high shear rate.
Methods
Preparation of human artery cryosections
The study protocol was approved by the institutional and
regional ethical board. Human iliac artery was removed from
deceased healthy organ donors, immediately frozen in 2-
methylbutane in dry ice and stored at )70  C. Cryosections
(6 lM thickness) of the artery were placed on poly-L-lysine-
coated slides (Poly-Prep Slides; Sigma-Aldrich Kft., Budapest,
Hungary) 1–3 days before the experiments and stored at
)20  C until use.
Model of platelet adhesion at high shear rate
The ﬂow-chamber model described previously was used [31].
Arterycross-sectionsonpoly-L-Lys-coatedslideswereperfused
in a parallel-plate chamber with citrate-anticoagulated blood
collected from healthy volunteers. A small parallel-plate cham-
ber was constructed on the slides using a 0.3-cm-wide and 1.5-
cm-long ﬂow channel cut into a piece of double-sided tape
(Scotch,1.27 cmwide,64 lMthick),whichwassandwichedtoa
methacrylate cover (2.3 cm · 3.8 cm) containing the inlet and
outlet tubing (1-mm internal diameter Tygon). The tissue
section waspositionedin the centerof theﬂowchannel between
theinletandoutletports.Assuminglaminarﬂowconditions,the
shearrateatthesurfaceofthesectionwas3350 s
)1,accordingto
theformula1.03*6Q/(w*h
2),whereQistheﬂowrateinmL s
)1,
w and h are the width and the height of the ﬂow path in cm,
respectively [32]. This shear rate was chosen as an adequate
modeloftherheologicalsituationinstenoticarteries[33].Before
the perfusion the sections were blocked with 2 w/v% bovine
serum albumin (BSA) in 0.05 mol L
)1 Tris buffer pH 7.4
containing 0.1 mol L
)1 NaCl and 0.02 w/v% NaN3 (BSA-
TBS) for 45 min. The 90-s perfusion was followed by a 30-s
wash with 1.5 mmol L
)1 KH2PO4, 8.1 mmol L
)1 Na2HPO4
buffer pH 7.4 containing 137 mmol L
)1 NaCl and
2.7 mmol L
)1 KCl (PBS) with 13 mmol L
)1 Na-citrate added.
Thereafter,thesectionswereﬁxedinacetoneat4  Cfor10 min.
Pretreatment of artery cryosections
Before perfusion cryosections were incubated with proteases,
isolated polymorphonuclear (PMN) cells or the supernatant of
the cells after 10-min activation with 1 lmol L
)1 formyl-
methionyl-leucyl-phenylalanine (fMLP; Sigma-Aldrich Kft).
The cell suspension or protease solution was applied in a 100-
lL volume on the surface of the cryosections and incubated for
30 min followed by washing three times with TBS. Enzyme
concentrations were 10 nmol L
)1 thrombin, 20 nmol L
)1
neutrophil elastase, 17 nmol L
)1 MMP-8 and 10 nmol L
)1
MMP-9. Cell count was adjusted to 6000 lL
)1 PMN cells in
PBS containing 5 mmol L
)1 glucose (PBS-glucose), which
corresponds to the normal count in human blood [34]. MMPs
secreted by PMN cells were activated with 1 mmol L
)1 4-
aminophenylmercuric acetate (APMA) for 30 min at 37  C.
Visualization of adherent platelets
Platelets adherent to the tissue were visualized by indirect
immunoﬂuorescence microscopy. The sections were blocked
with 200 lL BSA-TBS for 30 min followed by washing with
TBS. Afterwards they were incubated for 60 min with 100 lL
4 lgm L
)1 mouse monoclonal antibody against human CD41
GpIIb/IIIa (Biodesign International, Saco, ME, USA) diluted
in BSA-TBS. The slides were washed three times with
50 mmol L
)1 Tris-HCl, 100 mmol L
)1 NaCl, 0.02 w/v%
NaN3 pH 7.4 and 100 lL2lgm L
)1 Alexa Fluor 488 goat-
anti-mouse IgG (Invitrogen, Budapest, Hungary) in BSA-TBS
was added and then incubated for 30 min. The slides were
washed three times and glass coverslips were afﬁxed over a
drop of 50 v/v% glycerol in TBS. Confocal images were taken
from the slides using a Zeiss LSM510 confocal laser scanning
microscope equipped with a 20 · 1.4 objective (Carl Zeiss,
Jena, Germany). The green ﬂuorescent signal was acquired
using a 488-nm excitation laser line (10% intensity) and
emission was detected in the 500–530 nm wavelength range.
Data analysis of platelet adhesion to the vessel wall
The quantiﬁcation of platelets adhered to the vessel wall was
performed with the SCION IMAGE software (Scion Corp,
Frederick, MD, USA) selecting the region of interest, calcu-
lating its surface area in pixels and setting a threshold intensity
value for automatic identiﬁcation of the area covered by
adhered platelets. The area covered by platelets is reported in
percentage of the whole area as mean ± SEM from n=5–32
images. To estimate the statistical signiﬁcance of differences,
Studentst w o - s a m p l et-test was used.
Preparation of neutrophil granulocytes
Neutrophil granulocytes were isolated from the buffy coat
fraction of human blood (Hungarian Blood Supply Service,
Budapest, Hungary) [35], which was mixed with an equal
volume of 2 w/v% Dextran T500 (GE Healthcare Bio-
Sciences, Uppsala, Sweden) in saline followed by a centrifuga-
tion at 150 · g for 5 min. Platelet-rich supernatant was
discarded and the residual fraction was mixed again with an
equal volume of 2 w/v% Dextran T500 in saline and erythro-
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was mixed with an equal volume of PBS-glucose and centri-
fuged for 3 min at 400 · g. The cell pellet was washed with an
equal volume of PBS-glucose followed by centrifugation for
3m i n a t 4 0 0· g. The PMN leukocyte-rich fraction was
layered on an equal volume of Percoll (GE Healthcare Bio-
Sciences) and centrifuged for 5 min at 400 · g.T h es u p e r n a -
tant was removed and further centrifuged for 15 min at
800 · g. The PMN-rich pellet was washed in PBS-glucose
twice and centrifuged for 3 min at 400 · g. Isolated neutrophils
were resuspended in PBS-glucose containing 1 mmol L
)1
CaCl2. The cells were counted using an Abacus Junior B
Hematology Analyser (Diatron, Budapest, Hungary). For
activation of neutrophil granulocytes 1 lmol L
)1 fMLP was
used. MMP-release from isolated neutrophil granulocytes was
measured with a Human Biotrak ELISA system for MMP-9
(GE Healthcare Bio-Sciences) according to the manufacturers
instructions.
Atomic force microscopy and scanning electron microscopy
Atomic force microscopy (AFM) images of native, protease- or
neutrophil-treated non-ﬁxed cryosections of arteries were
acquired with a Nanoscope IIIa scanning probe microscope
(Digital Instruments, Santa Barbara, CA, USA). The mea-
surements were done in contact mode in air using cantilevers
with a force constant of 0.12 N m
)1 (Veeco Instruments Inc.,
Camarillo, CA, USA). Preparation, pre-treatment with various
agents and washing of cryosections were performed as
described above for the platelet adhesion procedure followed
by storage at )20  C until use. For scanning electron micros-
copy (SEM) evaluation the tissue samples were washed in
100 mmol L
)1 Na-cacodylate buffer pH 7.2, followed by
ﬁxation for 10 min with 1 v/v% glutaraldehyde in the same
buffer and dehydration in a dilution series of acetone and
hexamethyldisilazane [36]. Before dehydration for enhance-
ment of the proteoglycan structures in the SEM images the
vessel wall cryosections were stained overnight with 0.05 w/v%
Cupromeronic Blue (Sigma-Aldrich Kft) in 0.025 mol L
)1 Na-
acetate buffer pH 5.8 containing 2.5 v/v% glutaraldehyde and
0.3 mol L
)1MgCl2[37]. The dried specimens were mounted on
adhesive carbon discs, sputter coated with gold in SC7620
Sputter Coater (Quorum Technologies, Newhaven, UK) and
images were taken with scanning electron microscope EVO40
(Carl Zeiss Gmbh, Jena, Germany). Sampling bias was
excluded by repeating the measurements at least 10 times
covering the whole surface of each cryosection for the AFM
imaging and six times for the SEM imaging.
Puriﬁed enzymes
Active enzyme concentration of human neutrophil elastase
(Serva Electrophoresis Gmbh, Heidelberg, Germany) was
determined as described previously [38]. Recombinant human
MMP-8 and MMP-9 proenzymes (R&D Systems, Abingdon,
England) were activated with 1 mmol L
)1 p-aminophenylmer-
curic acetate (APMA; Sigma-Aldrich Kft) at 37  Cf o r1ha n d
24 h, respectively, and their activity was determined with
gelatin substrate zymography [39]. Chondroitinase ABC
(Sigma-Aldrich Kft) was used according to the preparation
activity stated by the manufacturer. Bovine thrombin was
purchased from Serva Electrophoresis Gmbh (Heidelberg,
Germany), thrombin was further puriﬁed by ion-exchange
chromatography on sulfopropyl-Sephadex yielding prepara-
tion with speciﬁc activity of 2100 IU mg
)1 [40] and recombi-
nant hirudin (Sigma-Aldrich Kft) was used for its inactivation.
MMP2/MMP-9 Inhibitor I [(2R)-2-[(4-biphenylylsulfo-
nyl)amino]-3-phenylpropionic acid] for the inhibition of
MMP-9 and MMP-Inhibitor I (4-Abz-Gly-Pro-D-Leu-D-
Ala-NHOH) for the inhibition of MMP-8 (Calbiochem,
LaJolla, CA, USA) were applied in combination at 5 lmol L
)1
concentration each. Pefabloc (aminoethyl-benzenesulfonyl-
ﬂuoride; Serva Electrophoresis Gmbh) was used for the
inhibition of serine proteases at 100 lmol L
)1 concentration.
Results
The changes in the vessel wall structure after exposure to
leukocytes or leukocyte-derived proteases were monitored by
high-resolution microscopy (AFM and SEM). AFM has the
potential to achieve submolecular resolution under physiolog-
ical conditions. Using this method, a ﬁnely pointed tip is moved
over the surface by a piezoelectric scanner; the undulations of
the tip are monitored with a laser-diode detector and translated
into a three-dimensional topographical image. This technique
was ﬁrst applied to study the ultrastructure of collagen ﬁbrils
and their association with proteoglycans in human cornea and
sclera [41,42]. The AFM images of native cryosections show a
compact structure of the media, in which the collagen ﬁbers are
covered by a homogeneous amorphous layer, while in the
adventitia the striped morphology of the collagen ﬁbers is
clearly visualized (Fig. 1A–C). The striped collagen structure in
the media layer is seen only after enzymatic or cellular pre-
treatment (Fig. 1D–H). In order to increase the electron
density of proteoglycans and prevent the complete collapse of
their structure, in SEM imaging we applied Cupromeronic
Blue, a cationic dye of well-characterized speciﬁcity for
proteoglycans and sulfated glycosaminoglycans [43], which
has been widely used in transmission and scanning electron
microscopy [44,45]. In native SEM images (Fig. 2A–C) the
rough collagen bundle-arrangement in the adventitia stands in
contrast with the bundle-free smooth surface of the media. Pre-
treatment with non-activated PMN cells does not alter the
media structure (not shown). Using Cupromeronic Blue
staining proteoglycans can be directly visualized on the surface
of collagen ﬁbers in the media, but not in the adventitia
(Fig. 2D–F). The Cupromeronic Blue staining is weak in the
adventitia indicating that collagen bundles are hardly covered
by proteoglycans, whereas the layer of the media shows a
strong Cupromeronic Blue signal because of proteoglycan
bunches. The speciﬁcity of Cupromeronic Blue staining for
proteoglycans in the applied artery specimens was conﬁrmed
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degrade proteoglycans and accordingly removes the proteo-
glycan-related SEM morphological signs, the ﬁne granular
staining in the media (compare Figs 2E and 3A). Activated
neutrophil granulocytes, neutrophil-derived proteases (elastase,
MMP-8, MMP-9) as well as thrombin also strip the proteo-
glycan meshwork off the media layer (Fig. 3B–F).
When citrated whole blood is perfused over cross-sections of
human iliac artery at a surface shear rate of 3350 s
)1, platelets
adhere mainly to the adventitia layer of the vessel wall and not
to the media (Fig. 4A). Platelet adhesion in this model can be
inhibited by an anti-VWF antibody, which blocks the VWF
binding to collagen [17]. In native sections the platelet coverage
of the adventitia is 23.39 ± 1.39%, while only 1.57 ± 0.25%
of the media is covered by platelets. Pre-treatment of vessels
with serine proteases at physiologically relevant concentrations
(about 10 nmol L
)1 thrombin is present in whole blood at the
point of clotting [46], 20 nmol L
)1 neutrophil elastase concen-
t r a t i o ni se x p e c t e di nc e l ls u s p e n s i o no fd e g r a n u l a t e dP M N s
[47–49]) promotes platelet adhesion to the media layer
(Fig. 4C). The plasma protease inhibitors present at a micro-
molar concentration in the perfused whole blood preclude
direct platelet effects of traces of protease from the pre-
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Fig. 1. Human iliac artery imaged using contact mode atomic force
microscopy (AFM). Artery cryosections were prepared and examined with
AFM as described in Methods. A–C, native unﬁxed adventitia and media
layers; D–H, media of cross-sections treated for 30 min with 4 nmol L
)1
chondroitinase ABC (D); 20 nmol L
)1 neutrophil elastase (E);
10 nmol L
)1 thrombin (F); 6000 lL
)1 polymorphonuclear (PMN) cells
activated with 1 lmol L
)1 formyl-methionyl-leucyl-phenylalanine (fMLP)
and1 mmol L
)14-aminophenylmercuricacetate(APMA)for10 minprior
the application tothearterycross-section (G)or 10 nmol L
)1MMP-9(H).
Scale bar = 1 lm. Each image is a representative of at least ﬁve sections.
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Fig. 2. Human iliac artery imaged scanning electron microscopy (SEM).
Artery cryosections were prepared for SEM examination as described in
Methods. Native, untreated cross-sections are shown in panels A–C,
whereas Cupromeronic Blue staining was used for enhancement of the
proteoglycan visualization in panels D–F. Each image is a representative
of at least ﬁve sections, in each of which six randomly selected ﬁelds were
observed at three levels of magniﬁcation (1000·,5 0 0 0 · and 10 000·).
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adventitia is not affected by these treatments (not shown). If
after treatment with 10 nmol L
)1 thrombin the arterial section
is exposed to 2 lmol L
)1 hirudin for 30 min, the media
coverage with platelets from whole blood circulated over the
section is the same as in a thrombin-treated section without
thrombin blockade (Fig. 4C). This control measurement
excludes direct platelet recruitment by traces of thrombin in
the pre-treated arterial sections, which could be hypothesized in
light of the known platelet-activating effects of thrombin.
Pre-treatment with isolated and fMLP-activated neutrophil
granulocytes increases the media platelet adhesion up to
18.11 ± 0.27% area coverage (Fig. 4D) and the supernatant
ofthesecellsyieldssimilarcoverageofthemedia(notshown).If
MMP activator (APMA) is also present, the thrombogenic
effect of activated neutrophils is enhanced (21.77 ± 0.61%
platelet coverage in the media layer), whereas MMP-inhibitors
(against MMP-8 and -9) signiﬁcantly moderate it (9.77 ±
0.56% coverage). In the presence of a broad-spectrum serine
protease inhibitor (Pefabloc) a similar moderate-level coverage
AD
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Thrombin
Fig. 3. The media layer of pretreated human iliac artery imaged by
scanning electron microscopy (SEM). Prior to staining with Cupro-
meronic Blue artery sections were treated for 30 min with 4 nmol L
)1
chondroitinase ABC (A), 20 nmol L
)1 neutrophil elastase (B),
10 nmol L
)1 thrombin (C), 6000 lL
)1 polymorphonuclear (PMN) cells
activated with 1 lmol L
)1 formyl-methionyl-leucyl-phenylalanine (fMLP)
and 1 mmol L
)1 4-aminophenylmercuric acetate (APMA) as in Fig. 1
(D), 17 nmol L
)1 MMP-8 (E), 10 nmol L
)1 MMP-9 (F). Scale
bar = 10 lm. Each image is a representative of at least ﬁve sections, in
each of which six randomly selected ﬁelds of the media layer were observed
at three levels of magniﬁcation (1000·, 5000· and 10 000·).
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Fig. 4. Platelet adhesion to distinct layers of the arterial wall. Human iliac
artery sections were incubated for 30 min with Tris-buﬀered saline (A) or
with PMN+fMLP+APMA (B, as an illustration of the treatments listed
in panel C and D). Thereafter, artery specimens were perfused with
citrated whole blood for 1.5 min at 3350 s
)1shear rate in the ﬂow chamber
described in Methods. Platelets were visualized by indirect immunoﬂuo-
rescence and images were analyzed for platelet coverage of the separate
layers (the media layer is indicated by asterisk). In panels C and D the area
in the media layer covered by platelets is shown in percentage of the total
m e d i aa r e a( m e a n±S E M ,n = 5–32) for the same experimental setup, in
which the 30-min treatment preceding the blood perfusion was performed
with various agents as indicated (in the sample labeled throm-
bin ﬁ hirudin the artery section was incubated for 30 min with hirudin
after a 30-min treatment with thrombin). PMN, 6000 lL
)1 PMN cells in
PBS-glucose; fMLP, 10-min activation of the cells with 1 lmol L
)1 fMLP
prior the application to the artery cross-section; APMA, 1 mmol L
)1
APMA; Pefa, 100 lmol L
)1 Pefabloc; MMP-I, a mixture of 5 lmol L
)1
MMP2/MMP-9 Inhibitor I and 5 lmol L
)1 MMP-Inhibitor I. Asterisk
indicates diﬀerence signiﬁcant at P < 0.001 level.
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The combined administration of MMP and serine protease
inhibitors completely abolishes the effect of neutrophils on the
platelet adhesion to the media (1.61 ± 0.07% coverage). Cells
which were not activated with fMLP did not inﬂuence
signiﬁcantly the platelet adhesion to the media layer
(2.43 ± 0.27% coverage). The release of MMP-9 from
activated neutrophils was measured as an indicator of degran-
ulation. After the same activation with fMLP as applied in the
experiments shown in Fig. 4, a single neutrophil granulocyte
secretes 0.075 pg MMP-9. Accordingly, the effects of puriﬁed
neutrophil proteases (MMP-8, MMP-9, neutrophil elastase)
were evaluated at concentrations relevant to such a degree of
degranulation[47–49].Theenhancementofplateletadhesionto
the media is reproduced by 17 nmol L
)1MMP-8, 10 nmol L
)1
MMP-9 or 20 nmol L
)1 neutrophil elastase (Fig. 4C).
Discussion
A ﬂow-chamber model, in which anticoagulated whole blood is
perfused through a channel over cross-sections of arteries at a
well-deﬁnedsurface shear rate, was used as a tool to analyze the
thrombin-independent phase of platelet deposition separately
from the subsequent thrombin-dependent platelet adhesion. In
this chamber the contact of circulating platelets with all arterial
wall layers models the situation at sites of incision injury or
atherosclerotic lesions [50] in blood vessels and allows explo-
ration of the thrombogenic potential of distinct vessel wall
layers. The application of arterial cryosections in this model
approximates the native structure of the vessel wall avoiding
gross mechanical perturbation of the wall architecture caused
by stripping off the intima in other models [16]. In addition, the
VWF-dependent nature of the platelet-vessel wall interactions
under the experimental conditions of the present study is well
characterized; an anti-VWF antibody, which blocks the VWF-
collagen interaction, inhibits the platelet adhesion to native
adventitia, as well as to chondroitinase ABC or acid-treated
media [17]. The two-stage treatment mode applied in our
experimental setup (pre-treatment of the vessel wall with PMN
cells or enzymes followed by perfusion with whole blood)
prevents promotion of platelet adhesion by direct interactions
between platelets and PMN cells. In addition, the abundant
protease inhibitors from the whole blood used in the second
stage eliminate any traces of proteases remaining in the artery
section from the ﬁrst stage of the assay. Thus, the observed
changes in platelet adhesion can be reliably attributed to the
vessel wall modiﬁcations induced in the ﬁrst stage of treatment
in our model.
Our present data conﬁrm that the thrombogenicity (platelet
bindingability)ofnativearterialmediaathighshearrateisvery
poor(Fig. 4A) in agreement with earlierreports [17,50].At sites
of incision injury or ruptured atherosclerotic lesions this
property may attenuate thrombus formation and thus a
counteracting mechanism should operate for efﬁcient platelet
plug formation. Because PMN cells are major components of
thrombiinﬂuencing both thrombus formationand lysis[51], we
hypothesized a novel function of these cells intheinitial stage of
thrombus formation: structural perturbation of the thrombo-
resistant media increasing its platelet-adhesive ability. Our data
(Fig. 4C,D)indicatethatashort(30-min)exposureofthemedia
to activated neutrophil cells or their supernatants profoundly
increases the adhesion of platelets to the media layer to a degree
similar to that in the adventitia. Perfusion of the cryosection
with these cells before perfusing with whole blood gave similar
results concerning platelet adhesion. This increase in thromb-
ogenicity is completely reversed by a combination of serine and
metalloproteinase inhibitors (Fig. 4D) in agreement with a
proteolytic mechanism underlying this cellular effect. Activated
PMN cells secrete proteases, which belong to two main enzyme
families, serine proteases (neutrophil elastase) and matrix
metalloproteinases (MMP-8 and MMP-9). Most of these
proteases remain membrane bound [52,53] and the tightly
adherent cells createa microenvironment from which inhibitors
are relatively excluded generating high local enzyme concen-
trations which overwhelm local defense mechanisms. The
elastase concentration is millimolar in azurophil granules and
exceeds the extracellular inhibitor concentrations by more than
two orders of magnitude, thus its release creates a pericellular
zone of activeproteolysis[48,49]. Thecontribution of MMPs to
thrombin-induced platelet-leukocyte aggregation is well char-
acterized under static conditions [54], but little is known of their
role at the interface of circulating blood and the vessel wall at a
stage of thrombus formation that precedes blood coagulation.
Our present ﬁndings show that partial proteolysis of the artery
cross-sections with each of these leukocyte-derived proteases
separately abolishes the thromboresistance of the media
(Fig. 4C). The impact of protease inhibitors on PMN-induced
platelet adhesion and the reproduction of the cell effects by
isolated PMN-derived proteases conﬁrm the proteolytic back-
ground of the thrombogenic changes in the media induced by
PMN cells.
Accordingtoanearlierreport[17]theplateletadhesioninour
experimental setup is mediated by VWF binding to collagen.
Because the role of the composition of the reactive matrix in
platelet adhesion is well established [55], we sought the differ-
ences in platelet adhesion to the native media and adventitia
layers, as well astotheprotease-modiﬁedmedia invariations of
structureandaccessibilityofthecollagenﬁbersinthevesselwall.
We approached the morphological features of the adhesive
substrateinthearterialwallwithSEMandAFManalysisofthe
arterycryosections.Thebasalstateoftheextracellularmatrixin
ourobservations(Figs 1and2)correspondstothehumanaortic
wall structures evidenced by SEM and AFM on cryofractured
samples [56]. Both microscopic techniques conﬁrm the free
accessibility of collagen ﬁbers in the adventitia (Figs 1A,B and
2A,C) in line with the high platelet-adhesive potential of this
layer (Fig. 4A). In contrast, no deﬁnite ﬁbrous pattern can be
distinguished in the AFM images of native media (Fig. 1C)
despite the known collagen content of this layer. The AFM
techniquecouldnotresolveanyfurtherdetailsinthearchitecture
of the native media probably because of the adhesion between
theAFMtipandtheamorphoussubstanceﬁllingtheinter-ﬁber
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of the native media isvisualizedasa ﬁnenetworksuperimposed
over the collagen ﬁbers (Fig. 2E,F). Based on the proteoglycan
speciﬁcity of the dye [37] and the effect of the chondroitinase
ABC treatment (Fig. 3A), we conclude that this ﬁne meshwork
represents proteoglycans intertwining the collagen ﬁbers. The
applied cellular (activated PMN) and enzymatic treatments
(elastase, MMP-8 and MMP-9), which remove this proteogly-
can network from the media observed with SEM (Fig. 3B–F),
expose the striped morphology of collagen ﬁbers seen on the
AFM images (Fig. 1E–H). These ﬁndings provide explanation
forthethromboresistanceofthenativemediaanditsproteolytic
abolishment. Proteoglycans are likely to be removed from
critical sites of collagen ﬁbers responsible for VWF binding.
Because of the complexity of the three-dimensional structure of
thecollagenﬁbers,thecurrentinformationonthelocationofthe
VWFbindingsitesincollagenisbasedprimarilyondatagained
withsynthetictriple-helicalpeptides,whichmapasinglebinding
site totheD2 periodof human collagenIII [57].Computational
and molecular visualization models of the native collagen
architecture clearly show that the proteolytic cleavage [58] or
ligand-interaction sites [59] in collagen may express variable
accessibility for proteases or ligands. Thus, in the context of the
arterial wall, proteoglycans in the media could easily mask the
VWFbindingsitesonthesurfaceofcollagenpreventingplatelet
adhesionathighshearrates,whereaspartialproteolysisexposes
these sites for interaction with VWF. Promotion of VWF-
collagen interaction does not require complete removal of the
proteoglycan matrix as evidenced by the thrombin effects.
Although thrombin causes only focal exposure of the collagen
ﬁbrils in the media (Fig. 1F), platelet adhesion is signiﬁcantly
increased (Fig. 4C). The modiﬁcation of the vascular structure
represents a novel aspect of the thrombin role in platelet plug
formation. While thrombin-mediated activation of platelets is
wellcharacterized[60],nodataareavailableonitsimpactonthe
extracellular matrix of the vessel wall.
In summary, our present data support the concept that
neutrophil-related proteolysis reverses the thromboresistance
of the native media layer of arteries and renders deeper vessel
wall layers platelet adhesive at sites exposed to blood (e.g. in
ruptured atherosclerotic plaques or incision injuries). Appreci-
ation of the in vivo role of this mechanism requires future
studies, which can substantiate new strategies for prevention of
atherothrombosis.
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